Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17 SEK | 0.00% | -1.16% | +9.96% |
Apr. 17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
Apr. 17 | Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US | CI |
Sales 2024 * | 617M 56.68M | Sales 2025 * | 773M 71.08M | Capitalization | 586M 53.84M |
---|---|---|---|---|---|
Net income 2024 * | -110M -10.11M | Net income 2025 * | -29M -2.67M | EV / Sales 2024 * | 1.42 x |
Net Debt 2024 * | 290M 26.66M | Net Debt 2025 * | 199M 18.29M | EV / Sales 2025 * | 1.01 x |
P/E ratio 2024 * |
-5.35
x | P/E ratio 2025 * |
-19.8
x | Employees | 116 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.49% |
Latest transcript on Orexo AB
1 week | -1.16% | ||
Current month | +9.11% | ||
1 month | +15.49% | ||
3 months | +17.57% | ||
6 months | +19.38% | ||
Current year | +9.96% |
Managers | Title | Age | Since |
---|---|---|---|
Nikolaj Sørensen
CEO | Chief Executive Officer | 52 | 11-09-30 |
Fredrik Järrsten
DFI | Director of Finance/CFO | 57 | 22-08-31 |
Edward Kim
CTO | Chief Tech/Sci/R&D Officer | - | 22-10-25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 19-04-10 | |
James Noble
CHM | Chairman | 65 | 20-04-15 |
Director/Board Member | 62 | 01-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 17 | 0.00% | 8,963 |
24-04-24 | 17 | +2.53% | 7,316 |
24-04-23 | 16.58 | +5.07% | 20,373 |
24-04-22 | 15.78 | -4.48% | 33,396 |
24-04-19 | 16.52 | -3.95% | 25,541 |
Delayed Quote Nasdaq Stockholm, April 25, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.96% | 53.78M | |
+4.16% | 70.78B | |
+10.61% | 9.15B | |
-17.03% | 4.84B | |
+37.51% | 4.22B | |
+3.92% | 3.92B | |
+18.14% | 2.55B | |
-24.13% | 2.26B | |
-29.70% | 2.24B | |
+9.09% | 1.92B |
- Stock Market
- Equities
- ORX Stock